Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR-Mutated Non–Small Cell Lung Cancer: Old or New Regimen? Clinical trials frequently include multiple end ...

View all available purchase options and get full access to this article. The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial ...

The conduct of cancer clinical research in the United States is supported by both private and public sponsors. Industry aims to obtain new drug approvals. Federally sponsored trials examine a broad ...

Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose ...

Correlative Science in the Cooperative Group System—Re-Engineering for Success Achieving opioid pharmacoequity or ensuring access to evidence-based pharmacologic therapies regardless of race and ...

Here, to our knowledge, we present the first known case of a patient with TAR syndrome who developed Philadelphia-chromosome positive (Ph+) AML, which accounts for only about 1% of newly diagnosed AML ...

Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose ...

This study examines the prevalence of symptoms of depression in women with breast cancer (n = 436) compared with those without breast cancer (n = 856) in Addis Ababa, Ethiopia, through a comparative ...

Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study ACP1-High tumors ...

Erratum: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, ...

Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005 In the article that ...